Physician profile
Marybeth Morgan
NPI 1235413675
$2,917.88
in general payments reported to CMS, 2019-2025
26 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $902 · 2022: $533 · 2023: $611 · 2024: $418 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.10 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.65 | 2021-2025 | |
| Novo Nordisk INC | $392.38 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $335.54 | 2021-2025 | Farxiga |
| Lilly USA, LLC | $261.40 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $258.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.87 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $182.62 | 2021-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $140.95 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.48 | 2022 | |
| Glaxosmithkline, LLC. | $104.17 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $67.41 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $41.16 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $37.55 | 2021 | |
| Bioventus LLC | $35.88 | 2022 | |
| Clarus Therapeutics INC. | $31.75 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $30.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.56 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $20.76 | 2023 | Camzyos |
| Currax Pharmaceuticals LLC | $16.81 | 2022 | |
| Almatica Pharma LLC | $16.78 | 2021 | |
| Insulet Corporation | $16.75 | 2023 | Omnipod |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $15.54 | 2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $15.13 | 2022 | |
| Merck Sharp & Dohme LLC | $12.39 | 2021 | |
| Genentech USA, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marybeth Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.